Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Maire Eloranta is active.

Publication


Featured researches published by Maire Eloranta.


Xenobiotica | 1990

Biotransformation of medetomidine in the rat

Jarmo S. Salonen; Maire Eloranta

1. The metabolites of a novel alpha 2-adrenoceptor agonist, medetomidine, in rat urine after subcutaneous administration at two dose levels (80 micrograms/kg or 5 mg/kg), and after incubation with rat liver fractions, were characterized by h.p.l.c., 1H-n.m.r and mass spectrometry. 2. Hydroxylation of a methyl substituent was the main biotransformation in vitro. Hydroxylation occurred at a rate sufficient for high metabolic clearance. 3. The major urinary metabolites were the glucuronide of hydroxymedetomidine (about 35% of urinary metabolites) and medetomidine carboxylic acid (about 40%). 4. Medetomidine unchanged represented about 1% or 10% of the urinary excretion products, dependent on dose. 5. A metabolic pathway consisting of hydroxylation with subsequent glucuronidation, or further oxidation to carboxylic acid, is suggested.


Journal of Steroid Biochemistry | 1990

Metabolism of toremifene in the rat

Hannu Sipilä; Lauri Kangas; Lauri Vuorilehto; Arm Kalapudas; Maire Eloranta; Marja Södervall; Reijo Juhani Toivola; Markku Anttila

Toremifene was labelled to a specific activity of about 20 microCi/mmol with tritium at positions 3 and 5 in the para-substituted phenyl ring. At these positions tritium is not eliminated within the metabolic pathways. A mixture of unlabelled and labelled toremifene (5 or 10 mg/kg, 5 microCi/mg) was given i.v. or p.o. to Sprague-Dawley rats. The elimination of radioactivity was followed up by collecting urine and feces daily for 13 days. The elimination of toremifene which was similar after p.o. and i.v. administration took place mainly in the feces. About 70% of the total radioactivity was eliminated within 13 days, of this amount more than 90% in the feces. All applied radioactivity could be detected in three separate fractions according to the oxidative state of the side chain when counted by Berthold TLC Linear Analyzer. Each fraction was further separated into single metabolites by TLC or HPLC. Altogether 9 metabolites were identified and almost all methanol-extractable components were identified. The main metabolic pathways in the rat were 4-hydroxylation and N-demethylation. The side chain was further oxidized to alcohols and carboxylic acids. Small amounts of unchanged toremifene were found in the feces both after p.o. and i.v. administration indicating biliary secretion.


European Journal of Drug Metabolism and Pharmacokinetics | 1988

Metabolism of detomidine in the rat. II. Characterisation of metabolites in urine.

Jarmo S. Salonen; Lauri Vuorilehto; Maire Eloranta; Arto Johannes Karjalainen

SummaryIn order to investigate the biotransformation of a new a2-adrenoceptor agonist, detomidine, metabolites were isolated from rat urine by solid phase extraction and purified by TLC. The isolated compounds were structurally analysed by1H-NMR, MS and GC-MS as such or as their methyl and/or silyl derivativesIn addition to detomidine, which was found in trace amounts, four major metabolites were identified: hydroxymethyldetomidine, the corresponding O-glucuronide, detomidine carboxylic acid, and detomidine mercapturate. Together the identified components make up about 80% of urinary detomidine derived compounds.On the basis of these findings a major biotransformation pathway could be suggested. The reaction sequence is initiated by a hydroxylation. Subsequent glucuronidation, glutathione conjugation or secondary oxidation divide the route into three branches each producing one of the other three identified metabolites.


Archive | 1996

Imidazole derivatives having affinity for alpha2 receptors activity

Arto Karjalainen; Paavo Huhtala; Juha-Matti Savola; Siegfried Wurster; Maire Eloranta; Maarit Savola; Raimo Saxlund; Victor Cockcroft; Arja Karjalainen


Archive | 1992

4(5) substituted imidazoles and their preparation and use

Arto Johannes Karjalainen; Raimo Virtanen; Arja Karjalainen; Maire Eloranta; Jarmo S. Salonen; Hannu Sipilä; Antti Haapalinna


Archive | 2008

Method for the preparation of therapeutically valuable triphenylbutene derivatives

Marja Södervall; Maire Eloranta; Arja Kalapudas


Archive | 2001

Imidazole derivatives having affinity for alpha2 receptors

Arto Karjalainen; Paavo Huhtala; Juha-Matti Savola; Siegfried Wurster; Maire Eloranta; Maarit Hillilä; Raimo Saxlund; Victor Cockcroft; Arja Karjalainen


Archive | 2008

Methods for the preparation of fispemifene from ospemifene

Marja Södervall; Maire Eloranta; Arja Kalapudas; Brian Kearton; Michael McKenzie


Archive | 1996

Enantiomers of 4-(5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole

Arto Johannes Karjalainen; Raimo Virtanen; Arja Karjalainen; Seppo Parhi; Maire Eloranta; Antti Haapalinna


Archive | 2014

Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase

Maire Eloranta; Leena Hirvelä; Lauri Kangas; Pasi Koskimies; Risto Lammintausta; Mikko Unkila

Collaboration


Dive into the Maire Eloranta's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge